NCT00964496View on ClinicalTrials.gov

Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2007

Study Completion Date

August 31, 2009

Conditions
Obscure Gastrointestinal BleedingAngiodysplasiaGastric Antral Vascular EctasiaThalidomide
Interventions
DRUG

Thalidomide

Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.

DRUG

Iron

Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT00964496 - Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation | Biotech Hunter | Biotech Hunter